Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1045 dose-escalation study in systemic lupus erythematosus and rheumatoid arthritis
jRCT2031250748Recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Single-arm trial of CN201 in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), sponsored by Merck & Co. Primary endpoints: Adverse events and Participant discontinuations due to adverse events. Started Sep 2026; status: recruiting.
02
Drugs
CN201
03
Conditions
systemic lupus erythematosus (SLE)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on jRCT2031250748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250748.